Evaluation of [Gd(Bz-TTDA)]2- as a potential contrast agent in MR imaging of the hepatobiliary system: An animal study

Journal of Magnetic Resonance Imaging

Volumn 20, Issue 4, 2004, Pages 632-639

  Hsu, Jui Sheng ^a   Jaw, Twei Shiun ^a   Liu, Gin Chung ^a   Wang, Yun Ming ^a   Chen, Shih Hsien ^a   Kuo, Yu Ting ^a   Jao, Jo Chi ^a   Li, Chun Wei ^a   Tsai, Kun Bow ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Contrast agents; Gd chelates; Hepatobiliary; Magnetic resonance imaging

Indexed keywords

4 BENZYL 3,6,10 TRIS(CARBOXYMETHYL) 3,6,10 TRIAZADODECANEDIOIC ACID; CONTRAST MEDIUM; GADOLINIUM CHELATE; GADOLINIUM PENTETATE MEGLUMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; HEPATOBILIARY SYSTEM; HISTOPATHOLOGY; KIDNEY CORTEX; KIDNEY MEDULLA; LD 50; LIVER; LIVER CELL CARCINOMA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT; SIGNAL NOISE RATIO;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CONTRAST MEDIA; DISEASE MODELS, ANIMAL; INJECTIONS, INTRAVENOUS; LETHAL DOSE 50; LIVER; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; ORGANOMETALLIC COMPOUNDS; RATS; RATS, WISTAR; SENSITIVITY AND SPECIFICITY;

EID: 4744375351     PISSN: 10531807     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmri.20151     Document Type: Article

References (31)

1. Hahn PF, Saini S. Liver-specific MR imaging contrast agents. Radiol Clin North Am 1998;36:287-297.
2. Clément O, Siauve N, Cuénod C-A, Vuillemen-Bodaghi V, Leconte I, Frija G. Mechanisms of action of liver contrast agents: impact for clinical use. J Comput Assist Tomogr 1999;23:S45-S52.
3. Van Beers BE, Gallez B, Pringot J: Contrast-enhanced MR imaging of the liver. Radiology 1997;203:297-306.
4. Helmberger T, Semelka RC. New contrast agents for imaging the liver. Magn Reson Imaging Clin N Am 2001;9:745-766.
5. Fahlvik AK, Klaveness J, Stark DD. Iron oxides as MR imaging contrast agents. J Magn Reson Imaging 1993;3:187-194.
6. Ni Y, Marchai G, Zhang X, et al. Uptake of manganese dipyridoxal- diphosphate by chemically induced hepatocellular carcinoma in rats: a correlation between contrast-media-enhanced magnetic resonance imaging, tumor differentiation, and vascularization. Invest Radiol 1993;28:520-528.
7. Marchal G, Zhang X, Ni Y, van Hecke P, Yu J, Baert AL. Comparison between Gd-DTPA, Gd-EOB-DTPA, and Mn-DPDP in induced HCC in rats: a correlation study of MR imaging, microangiography, and histology. Magn Reson Imaging 1993;11:665-674.
8. Ni Y, Marchai G, Yu J, Mühler A, Lukilo G, Baert AL. Prolonged positive contrast enhancement with Gd-EDB-DTPA in experimental liver tumors: potential value in tissue characterization. J Magn Reson Imaging 1994;4:353-363.
9. Ni Y, Marchai G, Lukito G, Yu J, Mühler A, Baert AL. MR imaging evaluation of liver enhancement by Gd-EOB-DTPA in selective and total bile duct obstruction in rats: correlation with serologic, microcholangiographic, and histologic findings. Radiology 1994;190:753-758.
10. Elizonodo G, Weissleder R, Stark DD, et al. Hepatic cirrhosis and hepatitis: MR imaging enhanced with superparamagnetic iron oxide. Radiology 1990;174:797-801.
11. Schuhmann-Giampierir G, Schmitt-Willich H, Press WR, Negishi C, Weinmann H-J, Speck U. Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system. Radiology 1992;183:59-64.
12. Petré C, Ni Y, Marchal G, et al. Detection and characterization of primary liver cancer in rats by MS-264-enhanced MRI. Magn Reson Med 1995;35:532-539.
13. Clément O, Mühler A, Vexler V, Bertherene Y, Brasch RC. Gadolinium-ethoxybenzyl-DTPA, a new liver-specific magnetic resonance contrast agent: kinetic and enhancement patterns in normal and cholestatic rats. Invest Radiol 1992;27:612-619.
14. de Haën C, Lorusso V, Luzzani F, Tirone P. Hepatic transport of the magnetic resonance imaging contrast agent gadobenate dimeglumine in the rat. Acad Radiol 1995;2:232-238.
15. Vogl TJ, Pegios W, McMahon C, et al. Gadobenate dimeglumine - a new contrast agent for MR imaging: preliminary evaluation in healthy volunteers. AJR Am J Roentgenol 1992;158:887-892.
16. Hamm B, Staks T, Mühler A, et al. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 1995;95:785-792.
17. 2+ by 3,6,10-tri(carboxymethyl)-3,6,10-triazadodecanedioic acid. J Chem Soc Dalton Trans 1998:4113-4118.
18. 5-[(s)-4-Bz- TTDA]) and its complexes formed with lanthanides, calcium (II), zinc(II), and copper (II) ions. Helv Chim Acta 2002;85:1033-1050.
19. Uggeri F, Aime S, Anelli PL, et al: Novel contrast agents for magnetic resonance imaging synthesis and characterization of the ligand BOPTA and its Ln(III) complexes (Ln=Gd, Ld, Lu). X-ray structure of disodium (TPS-9-145337286-C-S)-[4-carboxyl-5,8,11-tris (carboxymethyl)-1-phenyl-2-oxa-5, 8,11-triazatridecan-13-oato(5-) gadolinite (2-) in a mixture with its enantiomer. Inog Chem 1995;34:633-642.
20. Weinmann HJ, Schuhmann-Giampiepi G, Schmitt-Willich H, Vogler H, Frenzei, Gries H. A new lipophilic gadolinium chelate as a tissue-specific contrast medium for MRI. Magn Reson Med 1991;22,233-237.
21. Smith DF, Walborg Jr EF, Chang JP. Establishment of a transplantable ascites variant of a rat hepatoma induced by 3′-methyl-4- dimethylaminoazobenzene. Cancer Res 1970;30:2306-2309.
22. Reed LJ, Muench H. A simplex method of estimating fifty percent endpoints. Am J Hyg 1938;27:493-494.
23. Caudana R, Morana G, Pirovan GP, et al. Focal malignant hepatic lesions: MR imaging enhanced with gadolinium benzyloxylpropionic tetra-acetate (BOPTA)-preliminary results of phase II clinical application. Radiology 1996;199:513-520.
24. Torres CG, Lundy B, Sterud AT, McGill S, Gordo PB, Bjerknes HS. Mn-DPDP for MR imaging of the liver: results from the European phase 111 studies. Acad Radiol 1997;38:631-637.
25. Vogl TJ, Kummel S, Hammerstingl R, et al. Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA. Radiology 1996;200:59-67.
26. Grazioli L, Morana G, Federle MP, et al. Focal nodular hyperplasia: morphologic and functional information from MR imaging with gadobenate dimeglumine. Radiology 2001;221:731-739.
27. Manfredi R, Maresca G, Baron RL, et al. Delayed MR imaging of hepatocellular carcinoma enhanced by gadobenate dimeglumine (Gd-BOPTA). J Magn Reson Imaging 1999;9:704-710.
28. Yoshikawa Y, Inoue Y, Akahane M, et al. Phantom and animal studies of a new hepatobiliary agent for MR imaging: comparison of Gd-DTPA-DeA with Gd-EOB-DTPA. J Magn Reson Imaging 2003,18:204-209.
29. Schima W, Saini S, Petersein J, et al. MR imaging of the liver with Gd-BOPTA: quantitative analysis of T1-weighted images at two different doses. J Magn Reson Imaging 1999;10:80-83.
30. Pascolo L, Cupelli F, Anelli PL, et al. Molecular mechanisms for the hepatic uptake of magnetic resonance imaging contrast agents. Biochem Biophys Res Comm 1999;257:746-752.
31. Morisetti A, Bussi S, Tirone P, de Haën C. Toxicological safety evaluation of gadobenate dimeglumine 0.5 M solution for injection (MultiHance®). A new magnetic resonance imaging contrast medium. J Comput Assist Tomogr 1999;23:S207-S217.